Merck

Labroots Announces Agenda for its 7th Annual Drug Discovery & Development Virtual Event on February 21, 2024

Retrieved on: 
Thursday, February 15, 2024

YORBA LINDA, Calif., Feb. 15, 2024 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its 7th annual event in the Drug Discovery & Development Virtual Event Series. Hosted on February 21st and free to attend, attendees will experience the forefront of pharmaceutical innovation joining industry and academic leaders from around the world debating the latest, insightful scientific breakthroughs in this ever-evolving field.

Key Points: 
  • Focusing from pre-clinical development to clinical development, advances in the field of drug discovery and development will be explored shaping current and future challenges in drug research
    YORBA LINDA, Calif., Feb. 15, 2024 /PRNewswire-PRWeb/ -- Labroots , the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its 7th annual event in the Drug Discovery & Development Virtual Event Series .
  • The 2024 informative agenda covers a range of sessions spanning areas including Emerging Modalities in Drug Discovery and Preclinical Development, New Methods in Pharmacogenomics, and Biomarker Applications.
  • Use the hashtag #LRdrug to follow the conversation and connect with other members of the global Drug Discovery & Development community!
  • Follow @DrugDiscoveryLR on Twitter and @DrugDiscoveryandDevelopment on Facebook to connect with our specialist Drug Discovery & Development writers and stay up to date with the latest Trending News in Drug Discovery & Development.

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023

Retrieved on: 
Thursday, February 15, 2024

For the fourth quarter of 2023, total revenue was $1,598 million, an increase of 8% on an as-reported basis as well as excluding impact of foreign currency (ex-FX), compared with the fourth quarter of 2022.

Key Points: 
  • For the fourth quarter of 2023, total revenue was $1,598 million, an increase of 8% on an as-reported basis as well as excluding impact of foreign currency (ex-FX), compared with the fourth quarter of 2022.
  • Women’s Health revenue increased 7% on an as-reported basis, and increased 8% ex-FX in the fourth quarter of 2023 compared with the fourth quarter of 2022 driven primarily by strong growth in the company's fertility products, particularly Follistim AQ® (follitropin beta injection).
  • Revenue of Hadlima™ (adalimumab-bwwd) more than doubled in the fourth quarter of 2023 compared with the fourth quarter of 2022 as a result of continued uptake since its July 2023 launch in the U.S.
  • Established Brands revenue increased 3% as-reported and 3% ex-FX in the fourth quarter of 2023 despite the impacts of Volume Based Procurement (VBP) initiatives and a challenging operating environment in China.

Firefly Bio Debuts With $94 Million Series A Financing

Retrieved on: 
Thursday, February 15, 2024

Firefly Bio emerged from stealth mode with a $94 million Series A financing co-led by founding investor Versant Ventures and by MPM BioImpact alongside Decheng Capital and with participation from Eli Lilly & Company.

Key Points: 
  • Firefly Bio emerged from stealth mode with a $94 million Series A financing co-led by founding investor Versant Ventures and by MPM BioImpact alongside Decheng Capital and with participation from Eli Lilly & Company.
  • Firefly has developed a novel platform to treat cancer using degrader antibody conjugates (DACs).
  • Firefly was incubated in close collaboration with scientists at Versant’s Ridgeline Discovery Engine in the Basel Technology Park.
  • “At Firefly, we’ve assembled a unique talent base and platform to significantly advance this promising field,” said Jerel Davis, Ph.D., Managing Director at Versant and a Firefly board member.

INVNT™ Further Expands Service Offerings in Event Management Sector, Reinforcing Industry Leadership

Retrieved on: 
Wednesday, February 14, 2024

New York, NY, Feb. 14, 2024 (GLOBE NEWSWIRE) -- INVNT ™, the global leader in live brand storytelling, is proud to announce the continued expansion of its service offerings within the event management sector.

Key Points: 
  • New York, NY, Feb. 14, 2024 (GLOBE NEWSWIRE) -- INVNT ™, the global leader in live brand storytelling, is proud to announce the continued expansion of its service offerings within the event management sector.
  • Petrina Rosholt, CMP (Certified Meeting Professional), who has been with INVNT for 10 years, was promoted to Vice President of Account Services and Event Management.
  • “At INVNT, we have always been at the forefront of offering comprehensive event management services, seamlessly integrating logistics, planning, and project management to create engaging storytelling experiences.
  • The recent expansion of event management services further positions INVNT to meet the growing demands of a dynamic global market, reinforcing its commitment to innovation, customer service, and partnership.

Dr. Lisa Johnson-Pratt Joins Aspen Neuroscience as Senior Vice President, Therapeutic Program Lead

Retrieved on: 
Wednesday, February 14, 2024

SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Aspen Neuroscience, Inc., a private biotechnology company developing induced Pluripotent Stem Cell (iPSC)-derived cell therapies, announced that Lisa Johnson-Pratt, MD has joined the company's executive management team in a new role as Senior Vice President, Therapeutic Program Lead.

Key Points: 
  • SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Aspen Neuroscience, Inc., a private biotechnology company developing induced Pluripotent Stem Cell (iPSC)-derived cell therapies, announced that Lisa Johnson-Pratt, MD has joined the company's executive management team in a new role as Senior Vice President, Therapeutic Program Lead.
  • "We are delighted to welcome Dr. Johnson-Pratt to Aspen Neuroscience," said Damien McDevitt, PhD, Aspen Neuroscience president and chief executive officer.
  • "As we prepare to enter the clinic with our first-in-human trial for Parkinson's disease, we are deepening our investment in the company's development.
  • Lisa is a board director at Assembly Bio and Tracon Pharma, and is the board chair of Young People in Recovery.

Flamingo Therapeutics Announces First Patient Dosed in Phase II PEMDA-HN Study for Head and Neck Squamous Cell Carcinoma (HNSCC)

Retrieved on: 
Wednesday, February 14, 2024

The global study is planned to be conducted at study centers in the United States, Korea and the United Kingdom.

Key Points: 
  • The global study is planned to be conducted at study centers in the United States, Korea and the United Kingdom.
  • "We are grateful for the contribution of all participants in this study and for the support of our clinical collaborators at each site."
  • "Our site is very excited about being the first enrollment on this important head and neck trial.
  • I believe the combination of danvatirsen and pembrolizumab has tremendous promise to treat patients with head and neck cancer.

UNCF NAMES LEGENDARY EDUCATOR DR. JOHNNETTA BETSCH COLE AS PRESIDENT-IN-RESIDENCE AND CO-CHAIRPERSON OF ITS $1 BILLION CAPITAL CAMPAIGN

Retrieved on: 
Tuesday, February 13, 2024

Cole will serve as an ambassador for the campaign and advocate with UNCF-member presidents and her own network to help identify new supporters.

Key Points: 
  • Cole will serve as an ambassador for the campaign and advocate with UNCF-member presidents and her own network to help identify new supporters.
  • As president of Bennett College, Dr. Cole led a successful $50 million capital campaign.
  • “I am equally thrilled to echo Dr. Lomax’s sentiments about Dr. Cole coming on board as co-chairperson of our capital campaign.
  • It is also a profound honor and a joy to serve as a co-chairperson for the UNCF capital campaign,” said Dr. Cole.

House Select Committee Tours Ginkgo Bioworks, Previews Biofab1, Ginkgo's New Integrated Data Generation Facility Set to Launch in 2025

Retrieved on: 
Tuesday, February 13, 2024

Ginkgo provided a tour of its expansive facility and discussed its unique position as a provider of services that facilitate applications of biotechnology in companies of all sizes across the economy.

Key Points: 
  • Ginkgo provided a tour of its expansive facility and discussed its unique position as a provider of services that facilitate applications of biotechnology in companies of all sizes across the economy.
  • Biofab1 is expected to begin operations early next year and aims to significantly increase Ginkgo's capacity to generate biological data.
  • Last summer, Ginkgo announced a strategic partnership with Google Cloud aimed at leveraging Ginkgo's Foundry and large biological data assets to develop new, state-of-the-art LLMs.
  • Ginkgo leadership shared with the visiting Committee its view that, like in other AI applications, leadership in the bioeconomy will necessitate leading in the development of these AI models.

Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

Retrieved on: 
Tuesday, February 13, 2024

The combination portion of the study is designed to evaluate the potential for a synergistic effect of MDNA11 with KEYTRUDA® in patients with advanced solid tumors.

Key Points: 
  • The combination portion of the study is designed to evaluate the potential for a synergistic effect of MDNA11 with KEYTRUDA® in patients with advanced solid tumors.
  • “Dosing the first patient in the combination arm with MDNA11 and KEYTRUDA® is a significant milestone for Medicenna and are excited with the progress of our novel IL-2 superkine," said Fahar Merchant, PhD, President and CEO of Medicenna.
  • “By combining MDNA11 with KEYTRUDA®, we are building upon the promising data generated to date by MDNA11 as a single agent.
  • MDNA11, with its uniquely differentiating ‘beta-enhanced not-alpha’ features, continues to be a potential best-in-class next-generation IL-2 super-agonist for treatment of advanced solid tumors.

DATAcc by DiMe Launches Digital Strategy for Standardized Measurement of Physical Activity

Retrieved on: 
Tuesday, February 13, 2024

BOSTON, Feb. 13, 2024 /PRNewswire/ -- Today, the Digital Health Measurement Collaborative Community (DATAcc) by the Digital Medicine Society (DiMe) released a core set of digital measures for physical activity, providing a roadmap for leveraging digital tools to measure the '6th vital sign.' Researchers and healthcare professionals can now better assess and address the impact of exercise on an individual's well-being. The measures were developed in partnership with industry leaders following a cross-disciplinary, evidence-based research project. New resources – including ontologies, a decision tool, and illustrative scenarios – provide specific support to clinical researchers, healthcare providers and decision-makers, and digital health technology developers to effectively implement these new core measures.

Key Points: 
  • Core measures and other resources are now available to support an industry standard for digitally measured physical activity, increasingly recognized as the '6th vital sign'
    BOSTON, Feb. 13, 2024 /PRNewswire/ -- Today, the Digital Health Measurement Collaborative Community ( DATAcc ) by the Digital Medicine Society ( DiMe ) released a core set of digital measures for physical activity , providing a roadmap for leveraging digital tools to measure the '6th vital sign.'
  • The importance of physical activity to health has long been recognized, and technology exists today to seamlessly measure it in the broad population.
  • "This new core set of digital measures for physical activity will advance the industry by reducing duplicative efforts and speeding the path to discoveries that will benefit the patients we aim to serve," said Jennifer Goldsack, CEO of DiMe.
  • Building off this momentum and extending its portfolio of digital measures work , DATAcc is now convening a project team to build the business case for digital endpoints.